(Q43253826)

English

Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy

scientific article published on 27 October 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

D Villa

1

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

J M Connors

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

T N Shenkier

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

R D Gascoyne

4

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

L H Sehn

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

K J Savage

6

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

publication date

27 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1046-1052

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

CNS prophylaxis in lymphoma: who to target and what therapy to use.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Adult Burkitt leukemia and lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP432

21 January 2018

Identifiers

10.1093/ANNONC/MDP432

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43253826&oldid=2195572784"